Jihye Han

Jihye Han

Auto-generated profile, based on publicly available information

Jihye Han

Vanderbilt University, Nashville, Tennessee

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
ATAriadna Tibau
Ariadna Tibau
ARAlejandra Romano
Alejandra Romano
ILIan T T Liu
Ian T T Liu
JHJihye Han
Jihye Han
ECEdward R Scheffer Cliff
Edward R Scheffer Cliff
AKAaron S Kesselheim
Aaron S Kesselheim
Background: The FDA’s accelerated approval pathway expedites cancer drug approvals based on surrogate measures, while clinical benefit is assessed in post-approval confirmatory trials. Many confirmatory trials also rely on surrogate measures rather than overall survival (OS) or quality of life (QoL). We evaluated how often accelerated approvals demonstrate clinical benefits at the time of conversion to regular approval, and if not, how often OS, QoL, or substantial clinical benefit emerge post-conversion. Methods: This retrospective cohort study reviewed FDA cancer drug accelerated approvals converted to regular approval (1992-2021), with follow-up through December 2024. We assessed confirmatory trial endpoints (OS and QoL) at conversion and searched for updated evidence post-conversion. Clinical relevance was assessed using the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). Results: Of 77 confirmatory trials, 25 (32%) showed OS benefit at conversion; 52 (68%) relied on surrogate measures. After a median 5-year follow-up, OS benefit emerged for 7 (9%) additional indications. QoL benefit was shown in 9 (12%) confirmatory trials at conversion and in 4 (5%) post-conversion. Among 73 (95%) confirmatory trials scoreable by ESMO-MCBS, 34 (47%) met the substantial clinical benefit threshold at conversion. Of the 31 (97%) trials with a survival benefit evaluable by ESMO-MCBS, 19 of 24 (79%) met the threshold at conversion and 5 of 7 (71%) post-conversion. Conclusions: Once oncology drugs are converted from accelerated to full approval, new evidence of OS or QoL gains remains rare, underscoring the need to ensure such evidence is available at conversion. Patients should be informed of evidence variability, and the ESMO-MCBS can provide valuable guidance.


29 May 2026 in Health Affairs Scholar
Verified
Journal Article
Open access
BRBenjamin N Rome
Benjamin N Rome
AMAdrianna McIntyre
Adrianna McIntyre
JKJinwoo Kim
Jinwoo Kim
JHJihye Han
Jihye Han
AKAaron S Kesselheim
Aaron S Kesselheim
BSBenjamin D Sommers
Benjamin D Sommers
Introduction: Timely assessments of insurance coverage are limited by lags and unpredictable data availability. We assessed the performance of real-time prescription data as a proxy for state-level coverage changes. Methods: We analyzed correlations between quarterly state insurance coverage (Medicaid, private insurance, and uninsured) and counts of filled prescriptions per capita by payer (Medicaid, private insurance, and cash-pay/assistance programs) from 2013 to 2024. Regression models measured how predictive prescription counts were of within-state coverage changes. Results: Medicaid prescriptions per capita were strongly correlated with Medicaid coverage (ρ = 0.62). Cash-pay prescriptions per capita were moderately correlated with uninsured rates (ρ = 0.49). Private coverage correlations were weak. Correlations were stronger for adults (ρ = 0.74 for Medicaid, ρ = 0. 52 for uninsured) than children. Among adults, each 10% within-state increase in Medicaid prescriptions was associated with a 7.5% relative increase (95% confidence interval [CI], 5.7%–9.3%) in Medicaid coverage; each 10% increase in cash-pay prescriptions was associated with a 2.5% increase (95% CI, 1.0%–4.1%) in uninsured rates. Conclusions: Real-time prescription drug data are moderately to highly correlated with state-level coverage changes in Medicaid and uninsured rates, particularly for adults. These data may be useful for timely assessments of upcoming policies affecting Medicaid coverage.

13 October 2026 in Annals of Internal Medicine
Verified
Journal Article
Closed access
GCGrace Castle
Grace Castle
JHJihye Han
Jihye Han
HHHaiden A. Huskamp
Haiden A. Huskamp
NKNancy L. Keating
Nancy L. Keating
SDStacie B. Dusetzina
Stacie B. Dusetzina